Brief: Legochem Biosciences And Iksuda Enter Licensing Agreement For Antibody Drug Conjugate Program

LigaChem Biosciences

15/05/2020 14:09

May 15 (Reuters) - LegoChem Biosciences Inc  141080.KQ :
    * LEGOCHEM BIOSCIENCES AND IKSUDA ENTER LICENSING AGREEMENT
FOR
ANTIBODY DRUG CONJUGATE PROGRAM
    * LEGOCHEM BIOSCIENCES INC - WORLDWIDE LICENSE AGREEMENT
WITH
IKSUDA THERAPEUTICS FOR DEVELOPMENT AND COMMERCIALIZATION OF
LCB73
    * LEGOCHEM BIOSCIENCES INC - UNDER TERMS OF AGREEMENT,
IKSUDA WILL
MAKE AN UPFRONT PAYMENT OF $5 MILLION
    * LEGOCHEM BIOSCIENCES INC - CO IS ELIGIBLE TO RECEIVE
DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP
TO $222 MILLION

Source text for Eikon:  ID:nBw6ZsjnRa 
Further company coverage:  141080.KQ 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))